| Year |
Citation |
Score |
| 2024 |
Dincman TA, Karam JAQ, Giordano A, Li H, Drusbosky LM, Gourdin TS, Howe PH, Lilly MB. Genomic amplifications identified by circulating tumor DNA analysis guide prognosis in metastatic castration-resistant prostate cancer. Frontiers in Oncology. 13: 1202277. PMID 38450313 DOI: 10.3389/fonc.2023.1202277 |
0.326 |
|
| 2022 |
Babatunde OA, Pearce JL, Jefferson MS, Frey LJ, Angel PM, Drake RR, Allen CG, Lilly MB, Savage SJ, Hughes Halbert C. Racial Distribution of Neighborhood-Level Social Deprivation in a Retrospective Cohort of Prostate Cancer Survivors. Diseases (Basel, Switzerland). 10. PMID 36278574 DOI: 10.3390/diseases10040075 |
0.308 |
|
| 2022 |
Swami U, Zimmerman RM, Nussenzveig RH, Hernandez EJ, Jo Y, Sayegh N, Wesolowski S, Kiedrowski LA, Barata PC, Lemmon GH, Bilen MA, Heath EI, Nandagopal L, Babiker HM, Pal SK, ... Lilly M, et al. Genomic landscape of advanced prostate cancer patients with versus mutations as detected by comprehensive genomic profiling of cell-free DNA. Frontiers in Oncology. 12: 966534. PMID 36185208 DOI: 10.3389/fonc.2022.966534 |
0.334 |
|
| 2022 |
Bray AW, Duan R, Malalur P, Drusbosky LM, Gourdin TS, Hill EG, Lilly MB. Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer. The Prostate. PMID 35766303 DOI: 10.1002/pros.24400 |
0.357 |
|
| 2022 |
Wang X, Zhou Z, Turner D, Lilly M, Ou T, Jiang W. Differential Circulating Fungal Microbiome in Prostate Cancer Patients Compared to Healthy Control Individuals. Journal of Immunology Research. 2022: 2574964. PMID 35155686 DOI: 10.1155/2022/2574964 |
0.331 |
|
| 2022 |
Krisanits BA, Woods P, Nogueira LM, Woolfork DD, Lloyd CE, Baldwin A, Frye CC, Peterson KD, Cosh SD, Guo QJ, Spruill LS, Lilly MB, Helke K, Li H, Hanna GS, et al. Non-enzymatic glycoxidation linked with nutrition enhances the tumorigenic capacity of prostate cancer epithelia through AGE mediated activation of RAGE in cancer associated fibroblasts. Translational Oncology. 17: 101350. PMID 35091340 DOI: 10.1016/j.tranon.2022.101350 |
0.303 |
|
| 2021 |
Halbert CH, Jefferson M, Allen CG, Babatunde OA, Drake R, Angel P, Savage SJ, Frey L, Lilly M, Obi T, Obeid J. Racial Differences in Patient Portal Activation and Research Enrollment Among Patients With Prostate Cancer. Jco Clinical Cancer Informatics. 5: 768-774. PMID 34328797 DOI: 10.1200/CCI.20.00131 |
0.304 |
|
| 2020 |
Moses M, Niu A, Lilly MB, Hahn AW, Nussenzveig R, Ledet E, Manogue C, Cotogno P, Lewis B, Layton J, Agarwal N, Sartor O, Barata PC. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer Treatment and Research Communications. 24: 100193. PMID 32702615 DOI: 10.1016/J.Ctarc.2020.100193 |
0.392 |
|
| 2020 |
Halbert CH, Jefferson MS, Drake R, Lilly M, Savage SJ, Nahhas GJ, Price ST, Loftley AE, Bauer A. Social and clinical determinants of physical activity in prostate cancer survivors. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 32394247 DOI: 10.1007/S00520-020-05482-1 |
0.416 |
|
| 2020 |
Ledet EM, Lilly MB, Sonpavde G, Lin E, Nussenzveig RH, Barata PC, Yandell M, Nagy RJ, Kiedrowski L, Agarwal N, Sartor O. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer. The Oncologist. 25: 327-333. PMID 32297439 DOI: 10.1634/Theoncologist.2019-0115 |
0.461 |
|
| 2020 |
Jefferson M, Drake RR, Lilly M, Savage SJ, Tucker Price S, Hughes Halbert C. Co-morbidities in a Retrospective Cohort of Prostate Cancer Patients. Ethnicity & Disease. 30: 185-192. PMID 32269460 DOI: 10.18865/Ed.30.S1.185 |
0.44 |
|
| 2020 |
Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan A, Brufksy AM, Parker BA, Bridges BB, Agarwal N, et al. Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion mutations among patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32034076 DOI: 10.1158/1078-0432.Ccr-19-2933 |
0.302 |
|
| 2020 |
Drusbosky LM, Kiedrowski LA, Johnson K, Nagy R, Saam J, Bilen MA, Gupta NK, Lilly MB. Circulating tumor (ct) DNA-based comprehensive genomic profiling to identify microsatellite instability (MSI) and defective DNA damage repair (DDR) in prostate cancer (PCa) patients. Journal of Clinical Oncology. 38: 190-190. DOI: 10.1200/Jco.2020.38.6_Suppl.190 |
0.397 |
|
| 2020 |
Santos GFC, Prophet M, Gourdin TS, Drusbosky L, Ledet EM, Sartor AO, Sonpavde G, Lilly MB. Identification of actionable BRAF mutations and their genomic associations in advanced prostate cancer. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E17597 |
0.418 |
|
| 2020 |
Dincman T, Giordano A, Li H, Gourdin TS, Drusbosky L, Howe P, Lilly MB. Prognostic implications of gene amplifications identified by circulating tumor DNA (ctDNA) analysis in metastatic prostate cancer (mPC). Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E17594 |
0.466 |
|
| 2020 |
Brown SG, Sutton B, Biotidara T, Turner D, Wilson R, Lilly M. Abstract D062: Mechanistic insights into phase 1b/2 study of chitosan for pharmacologic manipulation of AGE (advanced glycation endproducts) levels in prostate cancer patients Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-D062 |
0.397 |
|
| 2020 |
Knowell AE, Nogueira LM, Biotidara T, Sutton B, Satterwhite A, Lilly M, Brown S, Turner D, Findlay V. Abstract A075: Lifestyle-associated metabolites drive neuroendocrine differentiation in prostate cancer Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-A075 |
0.407 |
|
| 2020 |
Walter KR, Ford FE, Gregoski MJ, Kramer RM, Knight KD, Spruill L, Nogueira LM, Krisanits BA, Taylor MH, Rue ACL, Lilly MB, Ambs S, Chan K, Turner TF, Varner H, et al. Abstract C024: Lifestyle-associated advanced glycation end products are elevated in ER+ positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention Cancer Epidemiology, Biomarkers & Prevention. 29. DOI: 10.1158/1538-7755.Disp18-C024 |
0.351 |
|
| 2020 |
Woods P, Krisanits BA, Foster D, Nogueira LM, Spruill L, Ford ME, Lilly MB, Findlay VJ, Turner DP. Abstract B047: Advanced glycation end products promote prostate tumor growth and are a potential biologic consequence of lifestyle factors contributing to cancer disparity Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp18-B047 |
0.428 |
|
| 2020 |
Rahmatpanah F, Robles GD, Mercola D, Lilly M, McClelland M. Abstract 1558: RNA expression differences between African Americans and European Americans prostate cancers in both their tumor-adjacent stroma and in their tumors Cancer Research. 80: 1558-1558. DOI: 10.1158/1538-7445.Am2020-1558 |
0.428 |
|
| 2019 |
Ou T, Zhou Z, Turner DP, Zhu B, Lilly M, Jiang W. Increased Preoperative Plasma Level of Microbial 16S rDNA Translocation Is Associated With Relapse After Prostatectomy in Prostate Cancer Patients. Frontiers in Oncology. 9: 1532. PMID 32010622 DOI: 10.3389/Fonc.2019.01532 |
0.401 |
|
| 2019 |
Ledet EM, Lilly MB, Sonpavde G, Lin E, Nussenzveig RH, Barata PC, Yandell M, Nagy RJ, Kiedrowski L, Agarwal N, Sartor O. Comprehensive Analysis of Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer. The Oncologist. PMID 31712304 DOI: 10.1634/theoncologist.2019-0115 |
0.362 |
|
| 2019 |
Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, ... ... Lilly MB, et al. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer. PMID 30620391 DOI: 10.1002/Cncr.31959 |
0.453 |
|
| 2019 |
Ko L, Lilly MB, Hahn AW, Nussenzveig R, Moses MM, Ledet E, Manogue C, Cotogno P, Lewis BE, Layton JL, Agarwal N, Sartor AO, Barata PC. Genomic changes of AR in ctDNA prior to enzalutamide in men with mCRPC after abiraterone acetate. Journal of Clinical Oncology. 37: 320-320. DOI: 10.1200/Jco.2019.37.7_Suppl.320 |
0.404 |
|
| 2019 |
Lin E, Hahn AW, Sonpavde G, Lilly MB, Nussenzveig R, Ledet E, Pal SK, Grivas P, Rich TA, Raymond VM, Sartor AO, Yandell M, Agarwal N. Discovery of targetable mutational signatures in advanced prostate cancer (aPC) using machine learning and next-generation sequencing (NGS) of circulating tumor DNA (ctDNA). Journal of Clinical Oncology. 37: 226-226. DOI: 10.1200/Jco.2019.37.7_Suppl.226 |
0.375 |
|
| 2019 |
Malalur PG, Gourdin TS, Roberts A, Lilly MB. Circulating tumor (ct) DNA-based genomic profile of prostate cancer (PCa) patients with elevated carcinoembryonic antigen (CEA). Journal of Clinical Oncology. 37: 218-218. DOI: 10.1200/Jco.2019.37.7_Suppl.218 |
0.402 |
|
| 2019 |
Mercola D, Rahmatpanah F, Agrawal A, Jia Z(, Zi X, Lilly MB, McClelland M. Immune-stimulatory gene expression in stroma cells of African-American prostate cancer tissues. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E16544 |
0.444 |
|
| 2019 |
Lin E, Hahn AW, Sonpavde G, Lilly MB, Nussenzveig R, Ledet E, Pal SK, Grivas P, Rich TA, Raymond VM, Sartor AO, Yandell M, Agarwal N. Profiling of genomic alterations in MAPK/ERK signaling in a large cohort of metastatic prostate cancer (mPC) patients. Journal of Clinical Oncology. 37: 5032-5032. DOI: 10.1200/Jco.2019.37.15_Suppl.5032 |
0.388 |
|
| 2018 |
Walter KR, Ford ME, Gregoski MJ, Kramer RM, Knight KD, Spruill L, Nogueira LM, Krisanits BA, Phan V, La Rue AC, Lilly MB, Ambs S, Chan K, Turner TF, Varner H, et al. Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention. Breast Cancer Research and Treatment. PMID 30368741 DOI: 10.1007/S10549-018-4992-7 |
0.317 |
|
| 2018 |
Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, et al. Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1800328. PMID 30339520 DOI: 10.1200/Jco.18.00328 |
0.312 |
|
| 2018 |
Ou T, Lilly M, Jiang W. The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer. Frontiers in Immunology. 9: 1188. PMID 29928275 DOI: 10.3389/Fimmu.2018.01188 |
0.424 |
|
| 2018 |
Ledet E, Lilly MB, Sonpavde G, Agarwal N, Nagy RJ, Sartor AO. Comprehensive analysis of AR alterations in cell free DNA from prostate cancer patients. Journal of Clinical Oncology. 36: 314-314. DOI: 10.1200/Jco.2018.36.6_Suppl.314 |
0.358 |
|
| 2018 |
Prophet M, Xiao K, Gourdin TS, Nagy RJ, Kiedrowski LA, Ledet E, Sonpavde G, Sartor AO, Lilly MB. Detection of actionable BRAF missense mutations by ctDNA-based genomic analysis in prostate cancer. Journal of Clinical Oncology. 36: 306-306. DOI: 10.1200/Jco.2018.36.6_Suppl.306 |
0.33 |
|
| 2018 |
Hahn AW, Ledet E, Stenehjem DD, Nussenzveig R, Braithwaite M, Maughan BL, Lilly MB, Sartor AO, Agarwal N. Association of genomic alterations (GAs) in circulating tumor DNA (ctDNA) with progression on abiraterone acetate (AA) or enzalutamide (enza) in advanced prostate cancer. Journal of Clinical Oncology. 36: 5048-5048. DOI: 10.1200/Jco.2018.36.15_Suppl.5048 |
0.467 |
|
| 2018 |
Bardia A, Rich TA, Raymond VM, Fairclough SR, Sartor AO, Lilly MB, Nezami M, Patel SP, Carneiro BA, Fan AC, Brufsky A, Parker BA, Bridges BB, Agarwal N, Maughan BL, et al. Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer. Journal of Clinical Oncology. 36: 12097-12097. DOI: 10.1200/Jco.2018.36.15_Suppl.12097 |
0.425 |
|
| 2017 |
Goicochea NL, Garnovskaya M, Blanton MG, Chan G, Weisbart R, Lilly MB. Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy. Protein Engineering, Design & Selection : Peds. PMID 29228299 DOI: 10.1093/Protein/Gzx058 |
0.401 |
|
| 2017 |
Rice LJ, Jefferson M, Briggs V, Delmoor E, Johnson JC, Gattoni-Celli S, Savage SJ, Lilly M, Prasad SM, Kittles R, Halbert CH. Discordance in perceived risk and epidemiological outcomes of prostate cancer among African American men. Preventive Medicine Reports. 7: 1-6. PMID 28507891 DOI: 10.1016/J.Pmedr.2017.04.010 |
0.411 |
|
| 2017 |
Liu G, Zhang J, Frey L, Gang X, Wu K, Liu Q, Lilly M, Wu J. Prostate-specific IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose tissue. Journal of Hematology & Oncology. 10: 14. PMID 28077171 DOI: 10.1186/S13045-016-0386-7 |
0.425 |
|
| 2017 |
Sonpavde G, Nagy RJ, Sartor AO, Pond GR, Gourdin TS, Nandagopal L, Ledet EM, Agarwal N, Carroll E, Naik G, Wang J, Bilen MA, Grivas P, Lanman RB, Talasaz A, ... Lilly MB, et al. Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy. Journal of Clinical Oncology. 35: 149-149. DOI: 10.1200/Jco.2017.35.6_Suppl.149 |
0.338 |
|
| 2017 |
Slavin TP, Banks K, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek M, Lilly MB, Sonpavde G, et al. Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing. Journal of Clinical Oncology. 35: 1514-1514. DOI: 10.1200/Jco.2017.35.15_Suppl.1514 |
0.374 |
|
| 2017 |
Rahmatpanah F, McGuire K, Lilly M, McClelland M, Mercola D. Abstract B04: The use of whole genome methylation scanning to define genes preferentially suppressed in African American Prostate Cancer Cancer Epidemiology, Biomarkers & Prevention. 26. DOI: 10.1158/1538-7755.Disp16-B04 |
0.429 |
|
| 2016 |
Gourdin TS, Lilly MB. Genomic profiling of metastatic prostate cancer through analysis of circulating tumor DNA (ctDNA). Journal of Clinical Oncology. 34: 174-174. DOI: 10.1200/Jco.2016.34.2_Suppl.174 |
0.396 |
|
| 2016 |
Sonpavde G, Nagy RJ, Agarwal N, Gourdin TS, Naik G, Eshaghian S, Wang J, Armstrong AJ, Vaishampayan UN, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB. Profiling of circulating tumor (ct)-DNA for potentially actionable targets in prostate cancer (PCa). Journal of Clinical Oncology. 34: 5035-5035. DOI: 10.1200/Jco.2016.34.15_Suppl.5035 |
0.42 |
|
| 2015 |
Li X, Yokoyama NN, Zhang S, Ding L, Liu HM, Lilly MB, Mercola D, Zi X. Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model. Oncotarget. PMID 26497688 DOI: 10.18632/Oncotarget.6166 |
0.507 |
|
| 2015 |
Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, Drake RR, Kraveka JM, Smith CD, Voelkel-Johnson C. The sphingosine kinase 2 inhibitor ABC294640 reduces the growth of prostate cancer cells and results in accumulation of dihydroceramides in vitro and in vivo. Molecular Cancer Therapeutics. PMID 26494858 DOI: 10.1158/1535-7163.Mct-15-0279 |
0.528 |
|
| 2015 |
Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, et al. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1601-8. PMID 25847934 DOI: 10.1200/Jco.2014.59.4127 |
0.42 |
|
| 2015 |
Lilly MB, Ma C, Yuan Y, Chen W, Soloff AC, McLaren CE, Zi X. A phase I trial of docetaxel combined with synthetic lycopene in subjects with metastatic prostate cancer. Journal of Clinical Oncology. 33: e16109-e16109. DOI: 10.1200/Jco.2015.33.15_Suppl.E16109 |
0.456 |
|
| 2015 |
Goicochea NL, Garnovskaya M, Blanton M, Chan G, Weisbart R, Lilly M. Abstract 642: Cell-penetrating bispecific antibodies for targeting androgen receptor signaling in advanced prostate cancer Cancer Research. 75: 642-642. DOI: 10.1158/1538-7445.Am2015-642 |
0.354 |
|
| 2014 |
Wang L, Li W, Lin M, Garcia M, Mulholland D, Lilly M, Martins-Green M. Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis. Carcinogenesis. 35: 2321-30. PMID 25023990 DOI: 10.1093/Carcin/Bgu145 |
0.444 |
|
| 2014 |
Jia Z, Lilly MB, Koziol JA, Chen X, Xia XQ, Wang Y, Skarecky D, Sutton M, Sawyers A, Ruckle H, Carpenter PM, Wang-Rodriguez J, Jiang J, Deng M, Pan C, et al. Generation of "virtual" control groups for single arm prostate cancer adjuvant trials. Plos One. 9: e85010. PMID 24465467 DOI: 10.1371/Journal.Pone.0085010 |
0.385 |
|
| 2013 |
Lilly MB, Koziol JA, Ruckle H, McLaren CE, Ahlering T, Skarecky D, Mercola D. Generation of virtual control groups for single-arm prostate cancer (PCa) adjuvant trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 239. PMID 28136822 DOI: 10.1200/Jco.2013.31.6_Suppl.239 |
0.36 |
|
| 2013 |
Twardowski PW, Beumer JH, Chen CS, Kraft AS, Chatta GS, Mitsuhashi M, Ye W, Christner SM, Lilly MB. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anti-Cancer Drugs. 24: 743-53. PMID 23652277 DOI: 10.1097/Cad.0B013E328361Feb0 |
0.487 |
|
| 2013 |
Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, Fruman DA. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 27: 586-94. PMID 23090679 DOI: 10.1038/Leu.2012.276 |
0.362 |
|
| 2012 |
Khan S, Jutzy JM, Valenzuela MM, Turay D, Aspe JR, Ashok A, Mirshahidi S, Mercola D, Lilly MB, Wall NR. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. Plos One. 7: e46737. PMID 23091600 DOI: 10.1371/Journal.Pone.0046737 |
0.436 |
|
| 2012 |
Li X, Liu Z, Xu X, Blair CA, Sun Z, Xie J, Lilly MB, Zi X. Kava components down-regulate expression of AR and AR splice variants and reduce growth in patient-derived prostate cancer xenografts in mice. Plos One. 7: e31213. PMID 22347450 DOI: 10.1371/Journal.Pone.0031213 |
0.43 |
|
| 2012 |
An N, Lin Y-, Liu A, Lilly M, Mahajan S, Kraft A, Kang Y. Serine/Threonine Pim Kinases Play an Important Role in Maintaining the Number and Function of Hematopoietic Stem Cells Biology of Blood and Marrow Transplantation. 18. DOI: 10.1016/J.Bbmt.2011.12.457 |
0.309 |
|
| 2011 |
Twardowski P, Chen C, Kraft AS, Chatta GS, Alexson E, Mitsuhashi M, Ye W, Lilly M. A phase II trial of dasatinib in subjects with hormone-refractory prostate cancer previously treated with chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4575. PMID 28023326 DOI: 10.1200/Jco.2011.29.15_Suppl.4575 |
0.486 |
|
| 2011 |
Romero Rosales K, Singh G, Wu K, Chen J, Janes MR, Lilly MB, Peralta ER, Siskind LJ, Bennett MJ, Fruman DA, Edinger AL. Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins. The Biochemical Journal. 439: 299-311. PMID 21767261 DOI: 10.1042/Bj20110853 |
0.398 |
|
| 2011 |
Kraft AS, Garrett-Mayer E, Wahlquist AE, Golshayan A, Chen CS, Butler W, Bearden J, Lilly M. Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biology & Therapy. 12: 119-24. PMID 21532336 DOI: 10.4161/Cbt.12.2.15723 |
0.332 |
|
| 2011 |
Tang Y, Parmakhtiar B, Simoneau AR, Xie J, Fruehauf J, Lilly M, Zi X. Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels. Neoplasia (New York, N.Y.). 13: 108-19. PMID 21403837 DOI: 10.1593/Neo.101092 |
0.463 |
|
| 2011 |
Basu A, Banerjee H, Rojas H, Martinez SR, Roy S, Jia Z, Lilly MB, De León M, Casiano CA. Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. The Prostate. 71: 755-65. PMID 21031435 DOI: 10.1002/Pros.21292 |
0.669 |
|
| 2011 |
Lin Y, An N, Liu A, Lilly MB, Kraft A, Kang Y. A Novel Role of Pim Serine/Threonine Kinases in Hematopoiesis: Pim 1 Kinase Increases Hematopoietic Stem Cell Population Blood. 118: 561-561. DOI: 10.1182/Blood.V118.21.561.561 |
0.341 |
|
| 2011 |
Fruman DA, Janes MR, Mallya S, Vu CC, Shieh MP, Lilly MB, Sender LS, Martin MB, Ren P, Liu Y, Rommel C. The TOR Kinase Inhibitor INK128 Is Effective in Pre-B Acute Lymphoblastic Leukemia Models Blood. 118: 2585-2585. DOI: 10.1182/Blood.V118.21.2585.2585 |
0.362 |
|
| 2010 |
Cen B, Mahajan S, Zemskova M, Beharry Z, Lin YW, Cramer SD, Lilly MB, Kraft AS. Regulation of Skp2 levels by the Pim-1 protein kinase. The Journal of Biological Chemistry. 285: 29128-37. PMID 20663873 DOI: 10.1074/Jbc.M110.137240 |
0.378 |
|
| 2010 |
Zemskova M, Lilly MB, Lin YW, Song JH, Kraft AS. p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase. Molecular Cancer Research : McR. 8: 1126-41. PMID 20647331 DOI: 10.1158/1541-7786.Mcr-10-0174 |
0.441 |
|
| 2010 |
Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nature Medicine. 16: 205-13. PMID 20072130 DOI: 10.1038/Nm.2091 |
0.384 |
|
| 2010 |
Basu A, Mediavilla-Varela M, Martinez S, Rojas H, Banergee H, Roy S, Lilly MB, Leon MD, Casiano CA. Abstract 2715: Peroxiredoxin 3: A potential biological determinant of prostate cancer health disparities Cancer Research. 70: 2715-2715. DOI: 10.1158/1538-7445.Am10-2715 |
0.68 |
|
| 2010 |
Basu A, Banerjee H, Rojas H, Martinez S, Mediavilla-Varela M, Sourav R, Jia Z, Mercola D, Lilly MB, Leon MD, Casiano CA. Abstract A108: Differential expression of peroxiredoxins in prostate cancer: Ethnic differences in the association of PRDX3 expression with clinical outcomes Cancer Epidemiology, Biomarkers & Prevention. 19. DOI: 10.1158/1055-9965.Disp-10-A108 |
0.687 |
|
| 2009 |
Mediavilla-Varela M, Pacheco FJ, Almaguel F, Perez J, Sahakian E, Daniels TR, Leoh LS, Padilla A, Wall NR, Lilly MB, De Leon M, Casiano CA. Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Molecular Cancer. 8: 68. PMID 19715609 DOI: 10.1186/1476-4598-8-68 |
0.723 |
|
| 2009 |
Beharry Z, Zemskova M, Mahajan S, Zhang F, Ma J, Xia Z, Lilly M, Smith CD, Kraft AS. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Molecular Cancer Therapeutics. 8: 1473-83. PMID 19509254 DOI: 10.1158/1535-7163.Mct-08-1037 |
0.507 |
|
| 2009 |
Zhang F, Beharry ZM, Harris TE, Lilly MB, Smith CD, Mahajan S, Kraft AS. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biology & Therapy. 8: 846-53. PMID 19276681 DOI: 10.4161/Cbt.8.9.8210 |
0.424 |
|
| 2008 |
Jiang F, Ruckle H, Ornstein D, Ahlering T, Howard F, Lilly M. Post prostatectomy multimodality adjuvant therapy for patients at high risk for prostate cancer relapse. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 16053. PMID 27947464 DOI: 10.1200/Jco.2008.26.15_Suppl.16053 |
0.384 |
|
| 2008 |
Shah N, Pang B, Yeoh KG, Thorn S, Chen CS, Lilly MB, Salto-Tellez M. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. European Journal of Cancer (Oxford, England : 1990). 44: 2144-51. PMID 18715779 DOI: 10.1016/J.Ejca.2008.06.044 |
0.459 |
|
| 2008 |
Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. The Journal of Clinical Investigation. 118: 3038-50. PMID 18704194 DOI: 10.1172/Jci33337 |
0.369 |
|
| 2008 |
Zemskova M, Sahakian E, Bashkirova S, Lilly M. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. The Journal of Biological Chemistry. 283: 20635-44. PMID 18426800 DOI: 10.1074/Jbc.M709479200 |
0.708 |
|
| 2008 |
Ebrahimi K, Ruckle H, Harper JD, Ornstein DK, Ahlering TE, Howard F, Lilly M. Post Prostatectomy Multimodality Adjuvant Therapy For Patients At High Risk For Prostate Cancer Relapse The Journal of Urology. 179: 558-559. DOI: 10.1016/S0022-5347(08)61643-2 |
0.418 |
|
| 2007 |
Holder S, Lilly M, Brown ML. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. Bioorganic & Medicinal Chemistry. 15: 6463-73. PMID 17637507 DOI: 10.1016/J.Bmc.2007.06.025 |
0.679 |
|
| 2007 |
Hansen JE, Fischer LK, Chan G, Chang SS, Baldwin SW, Aragon RJ, Carter JJ, Lilly M, Nishimura RN, Weisbart RH, Reeves ME. Antibody-mediated p53 protein therapy prevents liver metastasis in vivo. Cancer Research. 67: 1769-74. PMID 17308119 DOI: 10.1158/0008-5472.Can-06-3783 |
0.321 |
|
| 2007 |
Ma J, Arnold HK, Lilly MB, Sears RC, Kraft AS. Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A. Oncogene. 26: 5145-53. PMID 17297438 DOI: 10.1038/Sj.Onc.1210323 |
0.342 |
|
| 2007 |
Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW, Lilly MB. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Molecular Cancer Therapeutics. 6: 163-72. PMID 17218638 DOI: 10.1158/1535-7163.Mct-06-0397 |
0.721 |
|
| 2007 |
Hansen JE, Fischer LK, Nishimura RN, Chan G, Chang SS, Baldwin SW, Aragon RJ, Carter JJ, Lilly M, Weisbart RH, Reeves ME. 98 Antibody-Mediated P53 Protein Therapy Prevents Liver Metastasis In Vivo. Journal of Investigative Medicine. 55. DOI: 10.1097/00042871-200701010-00106 |
0.33 |
|
| 2006 |
Zemskova M, Wechter W, Bashkirova S, Chen CS, Reiter R, Lilly MB. Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase. Biochemical Pharmacology. 72: 1257-67. PMID 16949054 DOI: 10.1016/J.Bcp.2006.07.028 |
0.504 |
|
| 2006 |
Zhou J, Pan M, Loh S, Xie Z, Lim Y, Lilly M, Glaser K, Albert D, Davidsen S, Chen CS. ABT-869, a novel multi-target receptor tyrosine kinase inhibitor (RTKI), combined with chemotherapy is synergistic in the therapy of acute myeloid leukemia cells with FLT3-ITD mutation (FLT3-AML) Journal of Clinical Oncology. 24: 13064-13064. DOI: 10.1200/Jco.2006.24.18_Suppl.13064 |
0.398 |
|
| 2005 |
Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim family kinases enhance tumor growth of prostate cancer cells. Molecular Cancer Research : McR. 3: 443-51. PMID 16123140 DOI: 10.1158/1541-7786.Mcr-05-0007 |
0.491 |
|
| 2005 |
Fodor I, Timiryasova T, Denes B, Yoshida J, Ruckle H, Lilly M. Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. The Journal of Urology. 173: 604-9. PMID 15643273 DOI: 10.1097/01.Ju.0000143196.37008.2C |
0.314 |
|
| 2005 |
Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, Levis M, Small D. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood. 105: 1759-67. PMID 15498859 DOI: 10.1182/Blood-2004-05-2006 |
0.382 |
|
| 2004 |
Aho TLT, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. Pim‐1 kinase promotes inactivation of the pro‐apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site Febs Letters. 571: 43-49. PMID 15280015 DOI: 10.1016/J.Febslet.2004.06.050 |
0.392 |
|
| 2004 |
Lilly MB, Drapiza L, Sheth M, Zemskova M, Bashkirova S, Morris J. Expression of Cyclooxygenase-2 (COX-2) in Human Leukemias and Hematopoietic Cells. Blood. 104: 4336-4336. DOI: 10.1182/Blood.V104.11.4336.4336 |
0.376 |
|
| 2004 |
Lilly MB, Holder S, Zemskova M, Neidigh J. Use of a Homology Model of the PIM-1 Kinase To Identify Variant Flavonoids Having Selective Inhibitory Activity Against PIM-1. Blood. 104: 2566-2566. DOI: 10.1182/Blood.V104.11.2566.2566 |
0.696 |
|
| 2003 |
Yan B, Zemskova M, Holder S, Chin V, Kraft AS, Koskinen PJ, Lilly MB. The PIM-2 Kinase Phosphorylates BAD on Serine 112 and Reverses BAD-induced Cell Death Journal of Biological Chemistry. 278: 45358-45367. PMID 12954615 DOI: 10.1074/Jbc.M307933200 |
0.698 |
|
| 2002 |
Wu X, Daniels T, Molinaro C, Lilly MB, Casiano CA. Caspase cleavage of the nuclear autoantigen LEDGF/p75 abrogates its pro-survival function: implications for autoimmunity in atopic disorders. Cell Death and Differentiation. 9: 915-25. PMID 12181742 DOI: 10.1038/Sj.Cdd.4401063 |
0.574 |
|
| 1999 |
Lilly M, Sandholm J, Cooper JJ, Koskinen PJ, Kraft A. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene. 18: 4022-4031. PMID 10435626 DOI: 10.1038/Sj.Onc.1202741 |
0.344 |
|
| 1987 |
Tucker KA, Lilly MB, Heck L, Rado TA. Characterization of a new human diploid myeloid leukemia cell line (PLB-985) with granulocytic and monocytic differentiating capacity Blood. 70: 372-378. PMID 3475136 DOI: 10.1182/Blood.V70.2.372.Bloodjournal702372 |
0.324 |
|
| Show low-probability matches. |